We are live on ! Find out more
IGC icon

IGC Pharma
IGC

30 hedge funds and large institutions have $1.36M invested in IGC Pharma in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

0.71% less ownership

Funds ownership: 5.92% → 5.2% (-0.71%)

14% less funds holding

Funds holding: 35 → 30 (-5)

40% less capital invested

Capital invested by funds: $2.27M → $1.36M (-$907K)

44% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 9

Holders
30
Holders Change
-5
Holders Change %
-14.29%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
5
Closed
9
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$7K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$50.3K
2
State Street
State Street
Massachusetts
+$14.5K
3
UBS Group
UBS Group
Switzerland
+$6K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.86K
5
TRCT
Tower Research Capital (TRC)
New York
+$1.64K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$125K
2
Renaissance Technologies
Renaissance Technologies
New York
-$107K
3
VF
Virtu Financial
New York
-$37K
4
HF
HRT Financial
New York
-$25K
5
TSS
Two Sigma Securities
New York
-$14.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$323K – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$259K -$107K -299,324 -25%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$242K +$2.86K +8,033 +0.9%
BlackRock
4
BlackRock
New York
$198K – – –
Citadel Advisors
5
Citadel Advisors
Florida
$78.1K -$125K -350,246 -56%
State Street
6
State Street
Massachusetts
$56.5K +$14.5K +40,592 +25%
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$43.6K +$50.3K +140,997 +1,010%
Northern Trust
8
Northern Trust
Illinois
$31.9K – – –
DP
9
Dearborn Partners
Illinois
$23.8K – – –
LC
10
Lawood & Co
Pennsylvania
$21.1K +$26.7K +75,000 New
Goldman Sachs
11
Goldman Sachs
New York
$18.4K – – –
Fisher Asset Management
12
Fisher Asset Management
Washington
$12.2K – – –
Truist Financial
13
Truist Financial
North Carolina
$10.3K – – –
Commonwealth Equity Services
14
Commonwealth Equity Services
Massachusetts
$9.38K -$570 -1,600 -5%
XT
15
XTX Topco
Cayman Islands
$7.97K -$2.02K -5,679 -17%
TC
16
T3 Companies
New York
$5.63K +$7.13K +20,000 New
UBS Group
17
UBS Group
Switzerland
$5.58K +$6K +16,824 +553%
Morgan Stanley
18
Morgan Stanley
New York
$4.98K – – –
TRCT
19
Tower Research Capital (TRC)
New York
$4.05K +$1.64K +4,599 +47%
Group One Trading
20
Group One Trading
Illinois
$2.02K – – –
GWM
21
Geneos Wealth Management
Colorado
$840 – – –
Bank of America
22
Bank of America
North Carolina
$508 -$766 -2,150 -54%
CIBC Private Wealth Group
23
CIBC Private Wealth Group
Georgia
$184 – – –
CJ
24
Caitlin John
Michigan
$56 – – –
Jones Financial Companies
25
Jones Financial Companies
Missouri
$31 +$39 +110 New
1
2

IGC Hedge Fund Activity: Q4 2025 in Review

30 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2025, worth a combined $1.36M — down 40% from $2.27M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of IGC and 5 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 5 added.

The largest buyer was Susquehanna International Group, adding an estimated $50.3K. The largest seller was Citadel Advisors, cutting an estimated $125K.

  • 30 institutional investors held IGC Pharma (IGC) as of Q4 2025, down from 35 in Q3 2025.
  • Funds reported $1.36M of IGC Pharma stock for Q4 2025, down 40% quarter-over-quarter.
  • 5 funds opened new IGC Pharma positions in Q4 2025 and 9 closed out, a net change of -4 holders.
  • The largest IGC Pharma buyer in Q4 2025 was Susquehanna International Group, an estimated $50.3K added.
  • The largest IGC Pharma seller in Q4 2025 was Citadel Advisors, an estimated $125K sold.

Based on aggregated 13F filings for Q4 2025.